Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
about
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaLMO2 and BCL6 are associated with improved survival in primary central nervous system lymphomaIndividualized markers optimize class prediction of microarray dataBiomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies.MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous systemDifferential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomasDetection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.Primary central nervous system lymphoma in immunocompetent individuals: a single center experienceIntensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group.Gene expression and angiotropism in primary CNS lymphomaPD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.Current and emerging pharmacotherapies for primary CNS lymphoma.
P2860
Q27013785-0D444515-D702-40D4-A32C-25F1E3C36D55Q30389426-BB82446D-9853-48D7-A022-0BDA622280CBQ30478007-9D535F8F-A74E-41BF-B69E-E1B15A42AC7CQ34124475-B4B63FE6-D2FB-405B-9020-C2D91AF165B9Q34640550-DFC49EB2-6461-41E9-9144-61CF9FEFEEC8Q35225279-C35D0B02-A2D3-4D79-BD39-9226B01BCB6AQ35933199-09C36032-E370-481C-B6F3-07BC3AFBAC87Q36048764-91A46782-4CBB-4282-B3E3-9A14842C7198Q36759171-17160BB7-A673-4B0A-9722-084038982E15Q36825602-09667417-3C9F-474A-A87E-4A3EE6FA48D8Q36853408-A8CC1E51-551D-4F8F-A2FE-DF147181F931Q37122287-964CB579-F4F7-45C4-84F8-53B4D4C901C1Q37265785-BE17EA00-2B5B-4CC6-A6ED-FFC1E297F6BBQ38316675-CA500422-8D09-4336-BDC8-142ADFDCDC66Q39102913-419D683C-D477-489A-B34E-72B52A66DDD8Q42126754-141F0418-E35A-42D4-AACC-6F51E30C69F2
P2860
Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@en
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@nl
type
label
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@en
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@nl
prefLabel
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@en
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@nl
P2093
P1476
Expression of p53, c-Myc, or B ...... g immunocompetent individuals.
@en
P2093
Ayse P Dincer
Bal Kampalath
Brent Logan
Camellia Eshoa
Christopher Schultz
Chung-Che Chang
Ellen Bunyi-Teopengco
Sherrie L Perkins
P304
P356
10.1043/0003-9985(2003)127<208:EOPMOB>2.0.CO;2
P577
2003-02-01T00:00:00Z